PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,028,924 | +35.7% | 326,888 | +77.3% | 0.00% | 0.0% |
| Q2 2023 | $7,388,948 | -19.9% | 184,401 | -18.4% | 0.00% | 0.0% |
| Q1 2023 | $9,224,772 | +34.2% | 226,042 | +26.9% | 0.00% | 0.0% |
| Q4 2022 | $6,875,167 | -33.4% | 178,067 | -8.3% | 0.00% | 0.0% |
| Q3 2022 | $10,327,000 | -20.2% | 194,173 | -12.5% | 0.00% | 0.0% |
| Q2 2022 | $12,933,000 | -12.7% | 221,820 | +14.3% | 0.00% | 0.0% |
| Q1 2022 | $14,809,000 | +29.2% | 194,051 | +1.9% | 0.00% | 0.0% |
| Q4 2021 | $11,462,000 | +2.1% | 190,494 | -5.0% | 0.00% | 0.0% |
| Q3 2021 | $11,227,000 | +1.6% | 200,479 | +10.1% | 0.00% | 0.0% |
| Q2 2021 | $11,045,000 | -19.1% | 182,018 | -6.6% | 0.00% | -50.0% |
| Q1 2021 | $13,660,000 | +54.3% | 194,892 | +31.7% | 0.00% | +100.0% |
| Q4 2020 | $8,854,000 | -4.6% | 147,955 | -4.2% | 0.00% | 0.0% |
| Q3 2020 | $9,281,000 | +9.6% | 154,370 | -4.4% | 0.00% | 0.0% |
| Q2 2020 | $8,468,000 | +38.6% | 161,398 | -11.4% | 0.00% | 0.0% |
| Q1 2020 | $6,108,000 | +7.1% | 182,158 | +44.7% | 0.00% | 0.0% |
| Q4 2019 | $5,705,000 | +20.1% | 125,926 | +0.9% | 0.00% | 0.0% |
| Q3 2019 | $4,752,000 | -37.0% | 124,806 | -28.0% | 0.00% | 0.0% |
| Q2 2019 | $7,540,000 | -13.4% | 173,364 | -24.2% | 0.00% | 0.0% |
| Q1 2019 | $8,707,000 | -8.7% | 228,777 | +3.3% | 0.00% | -50.0% |
| Q4 2018 | $9,532,000 | -37.0% | 221,572 | -28.0% | 0.00% | -33.3% |
| Q3 2018 | $15,128,000 | +78.1% | 307,791 | +16.1% | 0.00% | +200.0% |
| Q2 2018 | $8,496,000 | -26.9% | 265,101 | -28.9% | 0.00% | -50.0% |
| Q1 2018 | $11,617,000 | -1.3% | 372,938 | +44.6% | 0.00% | +100.0% |
| Q4 2017 | $11,773,000 | +57.6% | 257,880 | +29.6% | 0.00% | 0.0% |
| Q3 2017 | $7,471,000 | -26.1% | 198,939 | -6.1% | 0.00% | -50.0% |
| Q2 2017 | $10,109,000 | -2.2% | 211,936 | -6.5% | 0.00% | 0.0% |
| Q1 2017 | $10,338,000 | -29.3% | 226,715 | -49.9% | 0.00% | -33.3% |
| Q4 2016 | $14,622,000 | +450.1% | 452,693 | +482.9% | 0.00% | +200.0% |
| Q3 2016 | $2,658,000 | -66.2% | 77,667 | -66.7% | 0.00% | -50.0% |
| Q2 2016 | $7,856,000 | -40.6% | 232,895 | -6.7% | 0.00% | -33.3% |
| Q1 2016 | $13,229,000 | -41.8% | 249,688 | -15.6% | 0.00% | -40.0% |
| Q4 2015 | $22,715,000 | +71.6% | 295,823 | -8.1% | 0.01% | +66.7% |
| Q3 2015 | $13,235,000 | +165.8% | 322,022 | +357.5% | 0.00% | +50.0% |
| Q2 2015 | $4,979,000 | -11.5% | 70,390 | +11.1% | 0.00% | 0.0% |
| Q1 2015 | $5,627,000 | -52.9% | 63,330 | -53.0% | 0.00% | -50.0% |
| Q4 2014 | $11,949,000 | +28.5% | 134,787 | +40.5% | 0.00% | +33.3% |
| Q3 2014 | $9,297,000 | +37.1% | 95,928 | +29.9% | 0.00% | +50.0% |
| Q2 2014 | $6,783,000 | +746.8% | 73,849 | +545.2% | 0.00% | – |
| Q1 2014 | $801,000 | -68.0% | 11,446 | -73.7% | 0.00% | – |
| Q4 2013 | $2,505,000 | +3070.9% | 43,584 | +2565.7% | 0.00% | – |
| Q3 2013 | $79,000 | -85.0% | 1,635 | -91.0% | 0.00% | – |
| Q2 2013 | $526,000 | – | 18,135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |